Prostate cancer trial will combine Alpharadin with Provenge

04/27/2012 | OncLive

In this video, Dr. Oliver Sartor of the Tulane Cancer Center in New Orleans explains a new trial approach that will use radiopharmaceutical radium-223 chloride, or Alpharadin, with the immunotherapy sipuleucel-T, or Provenge, to treat castration-resistant prostate cancer. Sartor said Alpharadin can release antigens, which makes cancer cells more vulnerable to treatments such as Provenge.

View Full Article in:

OncLive

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ